First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma MedDRA version: 18.1 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
Conditions
Interventions
Product Name: recPRAME(20µg)+AS15
Product Code: recPRAME(20µg)+AS15
Pharmaceutical Form: Powder and solvent for suspension for injection
Other descriptive name: PD1/3-PRAME-His protein
Concentration u
Sponsors
GlaxoSmithKline Biologicals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Male or female patient with histologically proven cutaneous melanoma. The stage of the disease is evaluated according to the classification of the American Joint Committee on Cancer, 2002. Phase I segment: All melanoma patients with stage IV M1b and stage IV M1c including completely resected stage IV patients but with the exception of stage IV M1c disease with serum lactate dehydrogenase (LDH) > 1.5 x Upper Limit of Normal (ULN) or with active involvement of the Central Nervous System (CNS). Note:Patients with a history of CNS involvement who have been treated by surgery or stereotaxic RT and whose disease has been under control for more than 6 months prior to the first administration of study treatment can be enrolled. Phase II segment: All melanoma patients with measurable, unresectable stage III melanoma including in-transit metastasis (with (N3) or without (N2c) nodal metastasis) and stage IV M1a melanoma. The patient should have documented progressive disease within 12 weeks of registration into the trial. Patients with resected stage IV and with stage IV M1b or M1c disease cannot be included. 2.Written informed consent for PRAME expression screening and gene profiling on resected tumor tissue and for the complete study has been obtained from the patient prior to shipment of the sample for expression testing and prior to the performance of any other protocol-specific procedure. 3.The patient is at least 18 years old at the time of signing the first Informed Consent Form. 4.The patient’s tumor shows expression of the PRAME antigen as determined by RT-PCR analysis or any updated technique on fresh tissue sample. 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6.The patient has adequate bone marrow reserve, renal, adrenal and hepatic function as assessed by standard laboratory criteria and defined as (with LLN/ULN signifying the lower/upper limit of normal, respectively): •Hemoglobin higher than 12 g/dL •Absolute leucocytes count equal to or higher than 3.0 x 10exp9/L •Absolute lymphocytes count equal to or higher than 1.0x10exp9/L •Platelet count equal to or higher than 100x 10exp9/L •Serum cortisol equal to or higher than LLN •Serum creatinine equal to or lower than ULN •Calculated creatinine clearance > 50 ml/min (according to Cockroft-Gault formula) •Total bilirubin equal to or lower than 1.5 x ULN (Except for patients with Gilbert's syndrome for whom the limit is equal to or lower than 2 x ULN) •Lactate dehydrogenase (LDH) LDH equal to or lower than1.5 x ULN in Phase I (except for patients with Gilbert's syndrome for whom the limit is equal to or lower than 2xULN) LDH equal to or lower than ULN in Phase II •Alanine transaminase (ALAT) equal to or lower than 2 x ULN •Aspartate aminotransferase (ASAT) equal to or lower than 2 x ULN These tests musts be done no more than 3 weeks before the first ASCI administration. 7.Female patients of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause. 8.Female patients of childbearing potential may be enrolled in the study, if the patient: •has practiced adequate contraception for 30 days prior to the study product administration, and •has a negative pregnancy test on the day of administration, and •has agreed to continue adequate contraception during the entire treatment period and for 2 months after the completion of the stud
Exclusion criteria
Exclusion criteria: 1.The patient has at any time received systemic chemotherapy, (bio)-chemotherapy, small molecules or CTLA-4 monoclonal antibodies for metastatic disease. Note: Isolated limb perfusion, as long as this was performed at least 4 weeks before registration into this trial, is authorized. 2.The patient is scheduled to receive any other anticancer treatment than those specified in the protocol, including but not limited to (bio)-chemotherapeutic or immunomodulating agents and radiotherapy. 3.The patient has received any cancer immunotherapy containing the PRAME antigen or any cancer immunotherapy for his/her metastatic disease. Note: Previous adjuvant treatment with interferon, anti-CTLA-4 monoclonal antibody or a cancer immunotherapeutic (“vaccine”) containing a tumor antigen other than PRAME is allowed, if the last administration of this was given at least 8 weeks before the first ASCI injection. 4.The patient requires concomitant treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents. Exception: The use of prednisone, or equivalent, at a dose of less than or equal to 0.125 mg/kg/day (absolute maximum 10 mg/day), inhaled corticosteroids or topical steroids is permitted. 5.Use of any investigational or non-registered product (drug or vaccine, except influenza vaccine) other than the study product within the 30 days preceding the first ASCI dose injection or planned use during the study period 6.The patient has (had) previous or concomitant malignancies at other sites (including carcinoma in situ), except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and is highly likely to have been cured. 7.The patient has an allergy to any component of the study investigational product or has a history of previous allergic reactions to vaccinations. 8.The patient has a history of confirmed adrenal dysfunction. 9.The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded. 10.The patient is known to be positive for the human immunodeficiency virus (HIV). 11.The patient has an uncontrolled bleeding disorder. 12.The patient has a family history of congenital or hereditary immunodeficiency. 13.The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures. 14.The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk. 15.For female patients: the patient is pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Co-primary objectives of the Phase I segment: To characterize •The occurrence of dose-limiting toxicity. •The anti-PRAME humoral immune response Co-primary objectives of Phase II segment: To characterize •The clinical activity in terms of objective response. •The occurrence of dose-limiting toxicity As of Amendment 3, there will no longer be an active follow-up of patients after discontinuation or completion of study treatment. The study will end approximately 30 days after the last dose will be administered. In addition, no more biological samples will be collected for protocol research purposes. For each biological sample already collected in the scope of the study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant. Sampling for safety monitoring will continue. ;Secondary Objective: For each dose tested in the Phase I segment and for the dose selected for the Phase II segment: To characterize •Additional clinical indicators of clinical activity in the overall study cohort and in the subgroup of patients who present the predictive MAGE-A3 gene signature. •Additional indicators of safety. •The specific humoral and cellular immune response elicited by the recPRAME + AS15 ASCI. As a result of the changes implemented in Amendment 3, specific humoral an cellular responses elicited by the recPRAME + AS15 ASCI will not be assessed further by default except if a scientific rationale remains relevant. ;Primary end point(s): Co-primary endpoints for the Phase I segment: 1. Dose-limiting toxicity endpoint •Occurrence of dose-limiting toxicity will be followed in all patients during the study treatment and until the end of follow-up. Criteria/definitions: •An ASCI related or possibly ASCI related grade 3 or higher toxicity. Grade 3 myalgia, arthralgia, headache, fever, rigors/chills and fatigue (including lethargy, malaise and asthenia) should persist for 48 hours despite therapy in order to be consi | — |
Secondary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: •AEs/SAEs: up to 30 days after the last treatment administration. •Anti-PRAME cellular and humoral response: at each timepoint samples will have been collected. •Clinical activity: Occurrence and duration of CR or PR, SD, MR, TTF, PFS, OS during the entire study. As of Amendment 3, there will no longer be an active follow-up of patients after disccontinuation or completion of study treatment. The study will end +/- 30 days after the last injection. In addition, no more biological samples will be collected for protocol research purposes. For each biological sample already collected in the scope of this study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant. Sampling for safety monitoring as per protocol will continue. ;Secondary end point(s): Secondary endpoints of the Phase I segment: •Safety endpoint: Occurrence of AEs and SAEs, including clinically significant abnormal hematological and biochemical values. •Immunogenicity endpoint: The anti-PRAME cellular (T-cell) response. The anti-PRAME, anti-protein D and anti-CpG humoral response. •Clinical activity endpoint:Occurrence of objective clinical responses (complete (CR) or partial (PR) response). Occurrence of stable disease (SD). Occurrence of mixed response (MR). Time to Treatment Failure (TTF). Progression-free survival (PFS). Overall survival (OS). The duration of response for patients with CR, PR or SD status. Secondary endpoints of the Phase II segment: •Safety endpoint:The secondary safety endpoints are identical to the secondary safety endpoints of the Phase I segment. •Clinical activity endpoint:The secondary clinical activity endpoints are identical to the secondary clinical activity endpoints of the Phase I segment except for CR/PR which are assessed as primary endpoints. •Immunogenicity endpoint:The secondary immunogenicity endpoints are the same as for the Phase I segment. A | — |
Countries
Czech Republic, France, Germany, Italy, Poland, Russian Federation
Contacts
Public ContactClinical Disclosure Advisor
GlaxoSmithKline Biologicals
Outcome results
None listed